To determine whether a variable definition of biochemical recurrence (BCR) based on clincopathologic features facilitates early identification of patients likely to suffer from disease progression.

June 6, 2011 (Washington, DC) — A post hoc analysis of a phase 3 clinical trial of the acute migraine drug dihydroergotamine (Levadex, MAP Pharmaceuticals Inc) using 4 different previously published ...

Prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer is widely used for reporting the outcome of radical prostatectomy (RP). A standardized BCR definition is lacking ...

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...